The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1177-1183

  Koivusalo, Riku ^a,b   Hietanen, Sakari ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; Chemotherapy; Human papillomavirus; p53

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BMS 184476; CARBOPLATIN; CARMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; MESSENGER RNA; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PROTEIN E6; PROTEIN P53; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CLONOGENESIS; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; GENOME; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN FUNCTION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WILD TYPE; APOPTOSIS; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 22144484889     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1340     Document Type: Article

References (37)

1. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690-8.
2. Rose PG. Combined-modality therapy of locally advanced cervical cancer. J Clin Oncol 2003; 21:211-7.
3. Savarese A, Cognetti F. New drugs in the treatment of recurrent or metastatic cervical cancer. Crit Rev Oncol Hematol 2003; 48:323-7.
4. Blagosklonny MV. p53: an ubiquitous target of anticancer drugs. Int J Cancer 2002; 98:161-6.
5. El Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22:7486-95.
6. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002; 12:53-9.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
8. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000; 97:8501-6.
9. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001; 98:1218-23.
10. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999; 18:7644-55.
11. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
12. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97:6693-7.
13. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 2000; 97:12513-8.
14. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90:5742-6.
15. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54:2287-91.
16. Fridman JS and Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22:9030-40.
17. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56:892-8.
18. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11:419-32.
19. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 2002; 62:7364-71.
20. Lipinski KS, Djeha AH, Krausz E, Lane DP, Searle PF, Mountain A, Wrighton CJ. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Ther 2001; 8:274-81.
21. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr., O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55:1649-54.
22. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000; 57:503-11.
23. Datta K, Shall P, Srivastava T, Mathur SG, Chattopadhyay P, Sinha S. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 2004; 11:525-31.
24. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
25. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-4.
26. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97:439-45.
27. Cascallo M, Calbo J, Gelpi JL, Mazo A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000; 7:545-56.
28. Fan S, El Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Jr., Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-30.
29. 2 to M transition: implications for gene therapy. Cancer Res 1997; 57:818-23.
30. Wang Y, Blandino G, Oren M, Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998; 17:1923-30.
31. Cimoli G, Valenti M, Ottoboni C, Parodi S. HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend? Int J Oncol 2001; 18:759-65.
32. Blagosklonny MV and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999; 83:151-6.
33. Nygren P, Csoka K, Larsson R, Busch C, Wester K, Malmstrom PU. Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. J Urol 1999; 162:2200-4.
34. Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M. Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Eur J Pharmacol 2001; 412:21-5.
35. Crook T and Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992; 11:3935-40.
36. Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB, Klinger HP. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996; 56:197-205.
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.